Press

Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights

Mar 2 • 3 min read

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and six months ended December 31, 2021. All results are reported under International Financial Reporting Standards and in Canadian dollars, unless otherwise specified. “We’re pleased to report record high…

HAVN Life Sciences Health Products Listed On Amazon

Feb 28 • 3 min read

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, announced that its portfolio of natural health products is now available through Amazon.com. The ecommerce giant carries the full line of HAVN Life’s natural health products launched last June, and ships to…

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

Feb 25 • 5 min read

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) (FSE: 31R) (“Revive”)…

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

Feb 24 • 5 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business. “With our end-of-phase II meeting now scheduled with the FDA, we…

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

Feb 23 • 6 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has successfully completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420